Efficacy and Safety of Glecaprevir (ABT-493)/Pibrentasvir (ABT 530) (GLE/PIB) in Combination With Sofosbuvir and Ribavirin in Participants With Hepatitis C Virus Who Did Not Respond to Treatment in a Previous AbbVie Clinical Study
Public ClinicalTrials.gov record NCT02939989. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Combination With Sofosbuvir and Ribavirin in Chronic Hepatitis C (HCV) Infected Subjects Who Have Experienced Virologic Failure in AbbVie HCV Clinical Studies (MAGELLAN-3)
Study identification
- NCT ID
- NCT02939989
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- AbbVie
- Industry
- Enrollment
- 33 participants
Conditions and interventions
Conditions
Interventions
- Sofosbuvir Drug
- Glecaprevir/Pibrentasvir Drug
- Ribavirin Drug
Drug
Eligibility (public fields only)
- Age range
- 12 Years to 99 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 20, 2016
- Primary completion
- May 6, 2021
- Completion
- Jul 29, 2021
- Last update posted
- May 3, 2022
2016 – 2021
United States locations
- U.S. sites
- 8
- U.S. states
- 8
- U.S. cities
- 8
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Digestive Health Specialists of the Southeast /ID# 155719 | Dothan | Alabama | 36305 | — |
| Ruane Clinical Research Group /ID# 155714 | Los Angeles | California | 90036 | — |
| Digestive Disease Associates - Baltimore /ID# 155713 | Baltimore | Maryland | 21229 | — |
| Henry Ford Health System /ID# 155720 | Detroit | Michigan | 48202 | — |
| University of Buffalo /ID# 155721 | Buffalo | New York | 14203 | — |
| Carolinas Center For Liver Dis /ID# 155731 | Statesville | North Carolina | 28677 | — |
| Gastro One /ID# 155729 | Germantown | Tennessee | 38138 | — |
| TX Liver Inst, Americ Res Corp /ID# 157881 | San Antonio | Texas | 78215 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 18 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02939989, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 3, 2022 · Synced Jul 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02939989 live on ClinicalTrials.gov.